Ambrisentan (Letairis) and Tadalafil (Adcirca) for Pulmonary Arterial Hypertension

被引：0
|
作者：
不详
机构：
来源：
MEDICAL LETTER ON DRUGS AND THERAPEUTICS | 2016年 / 58卷 / 1485期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：2 / 4
页数：3
相关论文
共 50 条
  • [21] An update on the use of ambrisentan in pulmonary arterial hypertension
    D'Alto, Michele
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2012, 6 (06) : 331 - 343
  • [22] A review of pulmonary arterial hypertension: role of ambrisentan
    Barst, Robyn J.
    VASCULAR HEALTH AND RISK MANAGEMENT, 2007, 3 (01) : 11 - 22
  • [23] Tadalafil Therapy for Pulmonary Arterial Hypertension
    Galie, Nazzareno
    Brundage, Bruce H.
    Ghofrani, Hossein A.
    Oudiz, Ronald J.
    Simonneau, Gerald
    Safdar, Zeenat
    Shapiro, Shelley
    White, R. James
    Chan, Melanie
    Beardsworth, Anthony
    Frumkin, Lyn
    Barst, Robyn J.
    CIRCULATION, 2009, 119 (22) : 2894 - U65
  • [24] Tadalafil for the treatment of pulmonary arterial hypertension
    Rosenzweig, Erika B.
    EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (01) : 127 - 132
  • [25] Tadalafil for the treatment of pulmonary arterial hypertension
    Klinger, James R.
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2011, 5 (03) : 315 - 328
  • [26] Tadalafil in primary pulmonary arterial hypertension
    Palmieri, EA
    Affuso, F
    Fazio, S
    Lembo, D
    ANNALS OF INTERNAL MEDICINE, 2004, 141 (09) : 743 - 744
  • [27] Improvement in Right Ventricular Strain with Ambrisentan and Tadalafil Upfront Therapy in Scleroderma-associated Pulmonary Arterial Hypertension
    Mercurio, Valentina
    Mukherjee, Monica
    Tedford, Ryan J.
    Zamanian, Roham T.
    Khair, Rubina M.
    Sato, Takahiro
    Minai, Omar A.
    Torres, Fernando
    Girgis, Reda E.
    Chin, Kelly
    Damico, Rachel
    Kolb, Todd M.
    Mathai, Stephen C.
    Hassoun, Paul M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197 (03) : 388 - 391
  • [28] Hemodynamics and risk assessment 2 years after the initiation of upfront ambrisentan-tadalafil in pulmonary arterial hypertension
    D'Alto, Michele
    Badagliacca, Roberto
    Lo Giudice, Francesco
    Argiento, Paola
    Casu, Gavino
    Corda, Marco
    Correale, Michele
    Ghio, Stefano
    Greco, Alessandra
    Lattanzio, Mariangela
    Mercurio, Valentina
    Paciocco, Giuseppe
    Papa, Silvia
    Prediletto, Renato
    Romeo, Emanuele
    Russo, Maria Giovanna
    Tayar, Alessandro
    Vitulo, Patrizio
    Vizza, Carmine Dario
    Golino, Paolo
    Naeije, Robert
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2020, 39 (12): : 1389 - 1397
  • [29] Ambrisentan ± tadalafil in WHO functional class II/III pulmonary arterial hypertension: a guide to its use in the EU
    Lyseng-Williamson K.A.
    Behr J.
    Drugs & Therapy Perspectives, 2018, 34 (7) : 289 - 299
  • [30] Initial combination therapy with ambrisentan plus tadalafil on pulmonary arterial hypertension-related hospitalization in the AMBITION trial
    Vachiery, Jean-Luc
    Galie, Nazzareno
    Barbera, Joan Albert
    Frost, Adaani E.
    Ghofrani, Hossein-Ardeschir
    Hoeper, Marius M.
    McLaughlin, Vallerie V.
    Peacock, Andrew J.
    Simonneau, Gerald
    Blair, Christiana
    Miller, Karen L.
    Langley, Jonathan
    Rubin, Lewis J.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2019, 38 (02): : 194 - 202
12345